Rare CNS focus Clinical-stage biotechnology with a lead asset CSTI-500 targeting Prader-Willi syndrome and related CNS disorders, presenting a niche opportunity for specialty pharma or patient advocacy collaborations seeking CNS disease solutions.

First-in-class assets CSTI-500 as a triple monoamine reuptake inhibitor and CSTI-200 GlyT-1 inhibitor in preclinical stage offer differentiated mechanisms, enabling partnership discussions around novel therapies or licensing in specific CNS indications.

Strategic licensing footprint Existing Greater China license for HBS-102 with Harmony Biosciences outside Greater China; potential for BD activity around regional expansion, co-development, or regional commercialization partnerships.

Clinical development readiness Phase I data showing CNS target engagement and tolerability supports engagement with CROs, patient recruitment networks, and potential shared-risk phase advancement opportunities for rare CNS diseases.

Financially lean collaboration Revenue in the low to mid seven-figure range and a small team indicates high value-for-cost partnerships, ideal for early-stage co-development deals, milestone-driven collaborations, or out-licensing opportunities.